Zentek launches Triera Biosciences
Canada-based Zentek has announced the launch of Triera Biosciences as its wholly owned subsidiary for its aptamer platform technology. This subsidiary now owns the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University.
The Company is repotedly taking this action following the strong, consistent pre-clinical results of its universal aptamer as a treatment against the SARS-CoV-2 virus including the latest Omicron XBB 1.5 variant and will continue to build upon its previous work on a rapid detection platform within the new subsidiary. Triera will offer a pure play in the biotech space when operated as an independent business and be more accessible to potential pharmaceutical partners, funders, and other interested parties.